See original story here Breast imaging analytics innovator Densitas Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its machine learning breast density assessment software. The software empowers radiologists with standardized, personalized and automated density reports to optimize women’s breast health and follow-up care decisions.“Receiving 510(k) clearance marks a significant milestone in our company’s growth as we expand our global reach into the U.S. market with our flagship product,” said Mohamed Abdolell, CEO of Densitas. We are delighted to be entering the largest medical device market in the world, especially as 31 states have passed mandatory breast density notification laws.” Breast density has been shown to be strongly associated with cancer risk. Densitas has the distinct advantage of facilitating breast density assessments of routinely stored standard processed images and their priors because the technology processes the same standard digital mammograms that radiologists view. This provides a practical solution for integrating breast density into risk-based models in population-based screening.The software is cleared for clinical use in the U.S., Europe, Canada and Australia, and is the first of several follow-on products. The software is being showcased at the European Congress of Radiology (ECR 2018), booth 114 at the Austria Center Vienna.About Densitas Densitas develops advanced imaging analytics technologies powered by machine learning that deliver actionable insights at point-of-care for personalized breast health. Our products address the key challenges facing breast imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines and standards, and delivery of appropriate care at sustainable costs. For more information, visit www.densitas.health]]>
BIONOVA CONTACT
#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]

Recent Posts
- MARS VR Lab
- Workinsights
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge
Business Wire National BioTech News
- Global Protein Labeling Market Report to 2028 - Featuring Thermo Fisher Scientific, Merck and PerkinElmer Among Others - ResearchAndMarkets.com
- Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
- Miravo Healthcare™ Announces Appointment of Anthony Snow to its Board of Directors
- Cybin Announces Results of Shareholders’ Meeting
- Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space
- Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
- Miravo Healthcare™ Announces Second Quarter 2022 Results
- Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
- Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
- Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements
RECENT NEWS
- MARS VR Lab January 25, 2022
- Workinsights January 25, 2022
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today November 2, 2021
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021
- NEWS RELEASE: BioNova supports the Government of Canada’s biomanufacturing and life sciences strategy July 30, 2021
RECENT TWEETS
Over half of #AVF2022 Company Showcase participants are health and life sciences companies. The Showcase features some of Atlantic Canada’s most promising technology companies.
https://t.co/Es7CQqgHJd https://t.co/T3EKmIjZLN
https://t.co/Es7CQqgHJd https://t.co/T3EKmIjZLN
Nova Scotia Health launches pilot program with @Virtual_Hallway to connect primary care providers with specialists to improve patient access to specialist care and reduce wait times.
@NSHealthHub @HealthNS @Doctors_NS @NSCollegeNurses https://t.co/RTZtDwz6Hq
@NSHealthHub @HealthNS @Doctors_NS @NSCollegeNurses https://t.co/RTZtDwz6Hq